Business Context and Reporting Period
Company: OSR Holdings, Inc. (OSRH)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: OSRH is a global healthcare holding company formed via a business combination with OSR Holdings Co., Ltd. (OSRK) on February 14, 2025. The company operates through three primary subsidiaries: Vaximm (oral immunotherapies for cancer), Darnatein (design-augmented biologics for degenerative diseases), and RMC (neurovascular medical device distribution in Korea). The company is classified as an "emerging growth company" and a "smaller reporting company."
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Net Sales | $2.91 million | $3.53 million |
| Gross Profit | $0.59 million | $0.81 million |
| Operating Loss | $(18.34) million | $(11.69) million |
| Net Loss | $(27.06) million | $(10.33) million |
| Cash and Cash Equivalents (Year End) | $1.70 million | $0.34 million |
| Accumulated Deficit | $(37.17) million | $(19.17) million |
| Short-term Borrowings | $2.32 million | $1.80 million |
| Derivative Liabilities | $2.53 million | $0 |
Note: The filing text does not provide a clear value for free cash flow; however, net cash used in operating activities was $(4.33) million for 2025.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 18% to $2.91 million, primarily due to RMC transitioning a supplier relationship to a consignment model (recognizing only commission revenue) and selling inventory back to a supplier that internalized distribution.
- Increased Operating Loss: Operating loss widened 57% to $18.34 million. This was driven by a 51% increase in SG&A expenses ($18.93 million vs. $12.50 million) due to professional fees and personnel costs associated with the business combination and public company compliance.
- Non-Operating Expenses: Other expenses increased significantly to $14.45 million, including approximately $8.5 million in one-time, non-cash merger-related expenses and $4.8 million in expenses related to warrants and convertible notes issued to White Lion Capital.
- Balance Sheet: Cash balances increased to $1.70 million, supported by proceeds from an Equity Line of Credit (ELOC) and financing activities, despite significant operating losses.
Guidance, Outlook, and Risks
Outlook and Strategy
- RMC Transformation: RMC is pivoting from a traditional distributor to a Fourth-Party Logistics (4PL) platform for the Korean healthcare supply chain. Management projects RMC revenue to grow from KRW 4.1 billion in 2026 to KRW 44.8 billion in 2030, driven by mandate acquisitions.
- Product Development: Vaximm plans to initiate Phase 2/3 trials for VXM01 (glioblastoma) in 2026. Darnatein anticipates entering clinical trials for DRT-101 (osteoarthritis) within 2-3 years.
- Capital Needs: The company expects to incur $2.5 million to $3.0 million in quarterly R&D expenses starting in late 2026, potentially rising to $5.0 million to $6.0 million.
Material Risks and Contingencies
- Going Concern: The auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows. The company relies on the ELOC (up to $80 million) and future financing.
- Nasdaq Compliance: The company received notice of non-compliance with the minimum bid price requirement ($1.00). It has been granted an extension until August 31, 2026, to regain compliance, potentially via a reverse stock split.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting as of December 31, 2025, specifically regarding the completeness of liabilities and sufficiency of accounting personnel.
- Related Party Transactions: Significant related party borrowings exist with BCM Europe AG, Bellevue Global Life Sciences Investors, and key management. A global license agreement for VXM01 with BCM Europe AG involves a royalty pass-through mechanism that could delay revenue recognition.
- Legal Proceedings: Pending civil actions include a claim by Benjamin Securities, Inc. ($425,000) and Chardan Capital Markets, LLC ($2.07 million).
Key Facts for Investor Verification
- Liquidity Runway: Verify the sufficiency of the $1.70 million cash balance against the projected quarterly burn rate and the availability of the $80 million ELOC facility.
- Going Concern Status: Confirm the status of the auditor's "substantial doubt" opinion and the company's specific plans to secure additional capital beyond the ELOC.
- Internal Control Remediation: Review the specific steps taken to remediate the material weaknesses in internal controls identified in the 2025 year-end evaluation.
- Nasdaq Listing: Monitor the stock price to ensure compliance with the $1.00 minimum bid price requirement by the August 31, 2026 deadline.
- RMC 4PL Execution: Assess the progress of RMC's strategic pivot to a 4PL model, including the acquisition of new mandates and the resolution of the terminated Penumbra distribution agreement.
- Related Party Terms: Scrutinize the terms of the VXM01 license agreement with BCM Europe AG, specifically the recovery mechanism for milestone payments and royalties.